Begin clinical trial in advanced B cell lymphoma
Delivered after the deadline (847 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 20 Dec 2021
- Due
- 30 Jun 2022
- Delivered
- 24 Oct 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“A clinical trial in advanced B cell lymphoma is anticipated to begin in the first half of 2022.”
What we found
Evidence strength B What the grades mean
Clinical trial in advanced B cell lymphoma began October 2024, significantly after the H1 2022 deadline.
-
B First Patients Dosed in Phase 1 Clinical Study
“October 24, 2024 — Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential of the company's CAR-NK cell therapy targeting CD-19 in the treatment of non-Hodgkin's lymphoma (NHL).” ✓ confirmed on the page
-
B ImmunityBio Announces Completion of $470 Million Post-Merger Financing
“A clinical trial in advanced B cell lymphoma is anticipated to begin in the first half of 2022.” ✓ confirmed on the page
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Clinical trial in advanced B cell lymphoma
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ImmunityBio, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-IBRX-002815 · Corrections policy